• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Amarin Corporation plc

    5/7/25 7:05:23 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRN alert in real time by email

    Unavailable

    Get the next $AMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRN

    DatePrice TargetRatingAnalyst
    11/20/2023Underweight
    JP Morgan
    10/25/2023$3.00 → $1.00Buy → Hold
    Jefferies
    1/6/2023$1.30 → $3.00Hold → Buy
    Jefferies
    5/6/2022Neutral → Underweight
    JP Morgan
    5/5/2022$10.00 → $3.00Outperform → Mkt Perform
    SVB Leerink
    5/5/2022$10.00 → $3.00Buy → Neutral
    H.C. Wainwright
    5/4/2022Outperform → Market Perform
    Northland Capital
    2/16/2022$11.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $AMRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cohen Paul converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:12 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sullivan Diane E. converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:07 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Odysseas Kostas D converted options into 838 units of American Depositary Shares and covered exercise/tax liability with 437 units of American Depositary Shares (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      4/22/25 9:00:09 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amarin Reports First Quarter 2025 Financial Results

      -- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo

      5/7/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

      -- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced it has regained compliance with the Nasdaq Stock Market ("Nasdaq") continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. On April 29, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of April 28, 2025 the Company's common stock had maintained an average closing share price of at least $1.00 over th

      4/29/25 4:15:00 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2025 financial results in the pre-market hours on May 7th. Conference Call and Webcast Information: Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062Intern

      4/28/25 4:15:00 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Berg Aaron bought $102,400 worth of Ordinary Shares (160,000 units at $0.64), increasing direct ownership by 25% to 805,380 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      8/5/24 5:30:03 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Holt Patrick bought $15,724 worth of Ordinary Shares (14,426 units at $1.09), increasing direct ownership by 5% to 314,426 units (SEC Form 4)

      4 - AMARIN CORP PLC\UK (0000897448) (Issuer)

      1/24/24 4:31:21 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

      DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s

      4/7/25 7:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Appoints Peter Fishman Chief Financial Officer

      DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said

      12/13/24 9:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Board of Directors Announces CEO Transition

      -- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron

      6/4/24 7:30:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Amarin

      JP Morgan resumed coverage of Amarin with a rating of Underweight

      11/20/23 7:16:51 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin downgraded by Jefferies with a new price target

      Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously

      10/25/23 6:25:52 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin upgraded by Jefferies with a new price target

      Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously

      1/6/23 7:26:32 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amarin Corporation plc (Amendment)

      SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)

      12/8/23 4:26:23 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

      SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

      12/5/23 7:30:10 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Amarin Corporation plc (Amendment)

      SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)

      9/5/23 4:15:30 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Amarin Corporation plc

      10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)

      5/7/25 7:05:23 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

      5/7/25 7:05:10 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Corporation plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AMARIN CORP PLC\UK (0000897448) (Filer)

      4/29/25 4:20:08 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMRN
    Financials

    Live finance-specific insights

    See more
    • Amarin Reports First Quarter 2025 Financial Results

      -- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing Compliance Regained Following Completed 1-For-20 ADS Ratio Change -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the first quarter of 2025. "As we begin 2025, our first quarter operational and financial performance reflects continued steady execution against our strategy to maximize the glo

      5/7/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

      DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company's first quarter 2025 financial results in the pre-market hours on May 7th. Conference Call and Webcast Information: Access to the live call:Go to the investor relations section of the Company's website at www.amarincorp.comDial in within the United States: 888-506-0062Intern

      4/28/25 4:15:00 PM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action

      -- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise -- -- Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the fourth quarter of 2024 and

      3/12/25 7:00:00 AM ET
      $AMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care